glp 1 parkinson's GLP-1 and Disease: Research, Benefits and Risks Repurposing glucagon-like peptide-1 receptor agonists

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

It contains enough for four weeks at the 2.5 mg starting dose, aligning perfectly with the first titration phase

Users frequently notice reduced local swelling, decreased warmth at the injury site, and subtle improvements in the angry quality of their pain

Saxenda has higher rates of gastrointestinal side effects than either and requires daily rather than weekly injections